Transpacific TAVR Registry

NCT03826264 · tracked via the Priya Life Science China tracker

Sponsor

Duk-Woo Park, MD

Phase

Observational

Started

2019-06-15

Last updated

2026-01-02

Condition(s) studied

Heart Valve DiseasesAortic Valve Insufficiency

Investigational drug(s) / intervention(s)

TAVR

TAVR: transcatheter aortic valve replacement (TAVR)

Study summary

This registry evaluates the long-term outcome of Transcatheter aortic valve replacement (TAVR) in real-world clinical practice.

Eligibility

Sex

ALL

Min age

19 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * All patients undergoing TAVR * Informed consent

Primary outcome measure(s)

Event rate of all cause death — 1 year

Trial sites (7)

Facility	City	Region	Status
Stanford University	Stanford	California	Recruiting
Northwestern Memorial Hospital	Chicago	Illinois	Recruiting
Second Affiliated Hospital of Zhejiang University	Hangzhou	China	Recruiting
Bucheon Sejong Hospital	Bucheon-si	South Korea	Active Not Recruiting
Chungnam National University Hospital	Daejeon	South Korea	Recruiting
Asan Medical Center	Seoul	South Korea	Recruiting
Seoul National University Hospital	Seoul	South Korea	Completed

More Duk-Woo Park, MD trials in China

Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Recruiting

Other trials for the same condition

AI Assisted Screening for VHD Using Routine Chest CT Scans Recruiting

Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome Recruiting

China Elderly Valve Disease Study III (China-DVD3 Study) Starting soon

ART Trial: Transcatheter J-VALVE Versus Surgery for Aortic Regurgitation Therapy Recruiting

Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03826264 on ClinicalTrials.gov ↗ ← All trials in China